

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

23rd December, 2022

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
--	--

Dear Sirs,

Sub: Disclosure under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI Listing Regulations”).

Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby wish to inform you that the Company has entered into a Securities Subscription Agreement and Shareholders’ Agreement dated 23rd December, 2022 with Enzene Biosciences Limited, a subsidiary of the Company (“Enzene”), Eight Roads Ventures India Healthcare IV, L.P. (“Eight Roads Ventures”) and F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”) in connection with an acquisition of a minority stake by Eight Roads Ventures and F-Prime Capital in Enzene.

In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure I. A copy of this disclosure will be made available on the Company’s website as well in accordance with Regulation 30(8) of the SEBI Listing Regulations.

Kindly take note of the same.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl: a/a



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

Annexure I

Particulars	Remarks
Name of the target entity, details in brief such as size, turnover etc.;	Enzene Biosciences Limited, a subsidiary of the Company (“Enzene”) having a turnover of Rs. 872.1 Million for the financial year ended 31 st March, 2022.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”;	Acquisition does not fall within the purview of related party transactions. None of the promoter/ promoter group/ group companies are interested in the acquisition.
Industry to which the entity being acquired belongs	Biosimilars and biologics contract manufacturing
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Funding to propel capacity expansions in India and United States of America (USA)
Brief details of any governmental or regulatory approvals required for the acquisition	NA
Indicative time period for completion of the acquisition;	The transaction is expected to be completed latest by 31 st January, 2023, subject to fulfillment of conditions precedent as described in the Securities Subscription Agreement.
Nature of consideration- whether cash consideration or share swap and details of the same	Cash consideration.
Cost of acquisition or the price at which the shares are acquired	Total Cash consideration of Rs. 1,614,834,249 (Rupees One Billion Six Hundred and Fourteen Million Eight Hundred and Thirty-Four Thousand Two Hundred and Forty-Nine).
Percentage of shareholding / control acquired and / or number of shares acquired;	% of shareholding – 8% post money on a fully diluted basis.



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);

Enzene was incorporated on 28th August, 2006 under the provisions of the Companies Act, 1956. It is engaged in the business of (i) research & development, manufacturing and out licensing of biosimilar products; and (ii) contract development and/or contract manufacturing for biosimilars, novel biologics, within India and/or outside India.

Turnover details:

FY 2019-2020: Rs. 96.6 Mn

FY 2020-2021: Rs. 326.6 Mn

FY 2021-2022: Rs. 872.1 Mn